Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.30 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain excitatory neurons (76 nCPM) | 1.00 |
| chemistry Open Targets | compounds already reach it: eszopiclone, flumazenil, secobarbital sodium +69 | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 2 Parkinson's papers of 161 | 0.85 |
| pathways Reactome | Reactome did not answer (Reactome: HTTP 429) | 0.00 |
No case: the score is under the bar. Receipt 1258
Sealed predictions
- GABRD in dopamine neurons, braak-0.20 (p 0.607) → -0.17 (p 0.663)receipt 1264
Swarm cases
receipt 1264: GABRD in dopamine neurons, braak
- power
- full sample -0.21 (p 0.408, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.21 (p 0.408, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.42 (p 0.084, n 18). could be the mix.
- skeptic
- leave-one-out range -0.31 to -0.10, sign flips 0; without severely affected donors -0.21 (p 0.408, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GABRD in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts